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Introduction:  Smoking  is  associated  with  atherosclerotic  disease,  but  there  is  controversy  about
its protective  nature  after  acute  coronary  syndrome  (ACS).
Objective:  To  determine  the  impact  of  smoking  on  the  presentation,  treatment  and  outcome
of ACS.
Methods:  We  analyzed  all  consecutive  patients  with  ACS  in  a  single  center  between  2005
and 2014.  Current  smokers  and  never-smokers  were  compared.  Independent  predictors  of  in-
hospital  mortality  and  of  a  composite  of  all-cause  mortality,  rehospitalization  for  cardiovascular
causes,  angiography,  percutaneous  coronary  intervention  and  coronary  artery  bypass  grafting
were  assessed  by  multivariate  logistic  regression.
Results:  A  total  of  2727  patients  were  included,  41.7%  current  smokers  and  58.3%  never-
smokers. Current  smokers  were  younger,  more  often  male,  had  fewer  comorbidities,  a  typical
clinical  presentation,  lower  heart  rate,  systolic  blood  pressure,  Killip  class,  BNP/NT-pro-BNP
and creatinine,  better  left  ventricular  systolic  function  and  less  severe  coronary  anatomy.  ST-
segment  elevation  myocardial  infarction  was  more  common  in  current  smokers.  Current  smokers
received  more  evidence-based  treatments  and  had  less  in-hospital  complications,  in-hospital
mortality  and  adverse  outcomes  at  one  year.  More  frequent  percutaneous  coronary  interven-
tion  at  one  year  was  noted  in  current  smokers.  Smoking  was  not  an  independent  predictor  of
outcome  when  the  multivariate  model  was  fully  adjusted  for  baseline  characteristics.
Conclusion: The  smoker’s  paradox  was  not  observed  in  this  population,  since  all  differences  in
outcome  were  explained  by  smokers’  more  benign  baseline  characteristics.
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Enfarte  do  miocárdio;
Tabagismo;
Fatores de  risco;
Mortalidade
O  paradoxo  dos  fumadores  nas  síndromes  coronárias  agudas  --  será  real?
Resumo
Introduc¸ão:  O  tabagismo  está  associado  à  doenc¸a aterosclerótica,  mas  persistem  dúvidas  sobre
a sua  natureza  protetora  após  a  ocorrência  de  uma  síndrome  coronária  aguda.
Objetivo: Determinar  o  impacto  do  tabagismo  na  apresentac¸ão,  tratamento  e  prognóstico  das
síndromes  coronárias  agudas.
Metódos: Analisámos  todos  os  doentes  consecutivos  com  síndrome  coronária  aguda  num  centro
único  entre  2005  e  2014.  Fumadores  activos  e  não-fumadores  foram  comparados.  Avaliámos
os  preditores  independents  de  mortalidade  intra-hospitalar  e  de  um  composto  de  mortalidade
por  todas  as  causas,  re-hospitalizac¸ão  de  causa  cardiovascular,  coronariograﬁa,  intervenc¸ão
coronária percutânea  e  cirurgia  de  revascularizac¸ão  miocárdica  através  de  regressão  logística
multivariada.
Resultados:  2727  dts  foram  incluídos,  41,7%  fumadores  e  58,3%  não-fumadores.  Os  fumadores
eram mais  jovens,  mais  frequentemente  do  género  masculino,  tinham  menos  comorbilidades,
uma  apresentac¸ão  clínica  típica  e  frequência  cardíaca,  pressão  arterial  sistólica,  classe  Killip,
BNP/NT-pro-BNP  e  creatinina  mais  baixos,  func¸ão  sistólica  do  ventrículo  esquerdo  mais  alta
e  doenc¸a coronária  menos  grave.  O  enfarte  agudo  do  miocárdio  com  supradesnivelamento
do segmento  ST  foi  mais  comum  nos  fumadores.  Os  fumadores  receberam  mais  frequent-
mente  tratamentos  baseados  na  evidência  e  tiveram  menos  complicac¸ões  e  mortalidade
intra-hospitalares e  eventos  adversos  no  primeiro  ano.  Uma  maior  taxa  de  intervenc¸ão  coro-
nária  percutânea  ao  primeiro  ano  foi  observada  nos  fumadores.  O  tabagismo  não  foi  um  preditor
independente  de  prognóstico  quando  o  modelo  multivariado  foi  ajustado  para  as  características
basais.
Conclusão:  O  paradoxo  dos  fumadores  não  foi  observado  nesta  populac¸ão,  uma  vez  que  todas
as diferenc¸as  no  prognóstico  foram  explicadas  pelas  características  basais  mais  benignas.
© 2018  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´  um





























iList  of  abbreviations
ACS acute  coronary  syndrome
BNP brain  natriuretic  peptide
CABG coronary  artery  bypass  grafting
CI conﬁdence  interval
DALYs disability-adjusted  life  years
NT-pro-BNP N-terminal  pro-brain  natriuretic  peptide
NSTEMI non-ST-segment  elevation  myocardial  infarc-
tion
OR  odds  ratio
PCI percutaneous  coronary  intervention
STEMI ST-segment  elevation  myocardial  infarction
ULN upper  limit  of  normal
ntroduction
obacco  smoking  is  the  leading  preventable  cause  of  death
orldwide1 and  the  second  leading  cause  of  disability-
djusted life  years  (DALYs)  lost.2 Smoking  is  strongly
ssociated with  the  development  of  atherosclerotic  disease,
articularly coronary  heart  disease.2 It  is  responsible  for  10%
f all  deaths  caused  by  cardiovascular  disease  and  31%  of
o
c
tALYs  lost  due  to  ischemic  heart  disease.2 However,  some
tudies reported  an  apparent  survival  beneﬁt  of  smokers
n the  setting  of  acute  coronary  syndrome  (ACS),  ranging
rom in-hospital  mortality3 to  three-year  mortality,4 a  phe-
omenon known  as  the  ‘smoker’s  paradox’.  Over  the  years,
his concept  has  been  widely  disputed  and  different  expla-
ations for  this  phenomenon  have  been  proposed,  based
n a biochemical  effect  or  on  unmeasured  confounding
actors.
Firstly, most  studies  that  reported  this  paradox  are  from
he pre-thrombolytic5,6 and  thrombolytic  eras,7--13 and  smok-
rs are  known  to  have  a  higher  thrombotic  burden,  which
ould confer  a  heightened  response  to  thrombolysis.14--16
econdly,  it  has  been  proposed  that  smokers  also  have  an
nhanced response  to  clopidogrel  therapy.17--22 Thirdly,  it
as been  noted  that  smokers  suffer  more  out-of-hospital
eath, thus  creating  a  selection  bias  when  assessing
n-hospital mortality.23,24 Lastly,  smokers  are  younger,
ave fewer  risk  factors  and  comorbidities  and  are  more
ggressively treated,  and  this  could  also  contribute  to  their
etter prognosis.13,25--27
Despite  this  evidence,  there  are  still  contemporary  stud-
es that  show  smoking  to  be  an  independent  predictor  of
12,28,29utcome.
To  shed  more  light  on  this  discrepancy,  our  study  aims  to
ompare the  characteristics  of  patients  with  ACS  according













sSmoker’s  paradox  in  acute  coronary  syndrome  
Methods
A  total  of  3298  consecutive  ACS  patients  were  admit-
ted to  our  tertiary  cardiology  center  between  2005  and
2014. Of  these,  203  patients  who  received  ﬁbrinolytic
therapy were  excluded,  due  to  its  possible  inﬂuence  on
outcome. The  remaining  patients  were  stratiﬁed  according
to self-reported  smoking  status:  current  smokers  (irre-
spective of  quantity),  never-smokers  and  former  smokers.
The 391  patients  included  in  the  latter  group  were  also
excluded from  the  analysis.  The  population  was  thus  com-
posed of  2727  subjects.  Demographic,  clinical,  laboratory,
echocardiographic, angiographic  and  treatment  data  were
collected.  This  was  a  retrospective  cohort  study,  but  all
data were  collected  prospectively  during  the  index  hospi-




Table  1  Baseline  characteristics  of  patients  admitted  with  acute
All  (n=2727)  Current  smo
Demographics
Age,  years  61±20  55±15  
Male  gender,  %  66.9  85.2  
Cardiovascular  risk  factors
Overweight/obesity,  %  65.0  60.9  
Family  history,  %a 12.0  16.3  
Hypertension,  %  65.6  48.2  
Diabetes,  %  26.0  14.7  
Dyslipidemia,  %  77.7  82.3  
Treated  hypertension,  %  43.4  25.4  
Treated  diabetes,  %  18.6  9.1  
Treated  dyslipidemia,  %  24.6  16.9  
Previous  history
CAD, %  35.8  29.7  
Stable  CAD,  %  23.5  19.8  
MI,  %  14.2  13.0  
PCI,  %  10.5  10.9  
CABG,  %  3.4  1.1  
Stroke/TIA,  %  5.9  2.6  
CKD,  %  2.7  1.0  
PAD,  %  3.1  4.0  
COPD,  %  2.0  2.9  
Cancer,  %  1.7  1.1  
Previous  medication
Aspirin, %  22.3  15.1  
P2Y12 inhibitor,  %  5.8  4.3  
ACEI/ARB,  %  33.8  19.2  
Beta-blocker,  %  16.6  10.9  
Statin,  %  25.1  17.2  
Oral  anticoagulation,  %  2.2  0.8  
Amiodarone,  %  1.3  0.4  
Oral  nitrate,  %  4.7  1.1  
CCB,  %  10.5  4.7  
Diuretic,  %  12.5  5.4  
a Family history of premature cardiovascular disease.
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin recept
artery disease; CCB: calcium channel blocker; CKD: chronic kidney disea
infarction; PAD: peripheral artery disease; PCI: percutaneous coronary849
nd  a  composite  of  all-cause  mortality,  rehospitalization
or cardiovascular  causes,  angiography,  percutaneous  coro-
ary intervention  (PCI)  and  coronary  artery  bypass  grafting
CABG) at  one  year  after  discharge.  Categorical  variables
ere expressed  as  percentages  and  continuous  variables  as
edians ±  interquartile  range.  A  family  history  of  prema-
ure cardiovascular  disease  was  deﬁned  as  a  ﬁrst-degree
amily member  with  a diagnosis  of  atherosclerotic  cardio-
ascular disease  before  the  age  of  55  (for  men)  or  65  years
for women).  There  was  a change  in  laboratory  availabil-
ty of  N-terminal  pro-brain  natriuretic  peptide  (NT-pro-BNP)
o brain  natriuretic  peptide  (BNP)  in  our  center  during  the
tudy period.  Therefore,  these  values  are  expressed  as  the
umber of  times  above  the  upper  limit  of  the  normal  ref-
rence range  (ULN).  Categorical  data  were  analyzed  by  the
hi-square test  and  continuous  data  by  the  Mann-Whitney
 coronary  syndrome  according  to  smoking  status.































or blocker; CABG: coronary artery bypass grafting; CAD: coronary
se; COPD: chronic obstructive pulmonary disease; MI: myocardial











































 test.  Logistic  regression  models  were  used  to  assess  for
ndependent predictors  of  the  clinical  outcomes.  Two-sided
-values <0.05  were  considered  statistically  signiﬁcant.
esults
f  the  2727  patients,  41.7%  (n=1138)  were  current  smokers
nd 58.3%  (n=1589)  never-smokers.
Baseline  characteristics  differed  substantially  between
urrent smokers  and  never-smokers  (Table  1).  Smokers  were
igniﬁcantly  younger  than  never-smokers  and  more  fre-
uently male.  They  had  less  classic  cardiovascular  risk
actors, except  for  dyslipidemia  and  family  history  of  pre-
ature cardiovascular  disease,  which  were  more  common  in
mokers. Previous  history  of  coronary  artery,  cerebrovascu-
ar and  chronic  renal  disease  were  less  common  in  smokers,
hile chronic  obstructive  pulmonary  and  peripheral  artery
isease were  more  common,  although  the  overall  prevalence
as low.  Smokers  received  less  treatment  for  risk  factors  and
ad less  cardiovascular  medication  at  admission.
A  typical  clinical  presentation,  with  lower  heart  rate,
ystolic blood  pressure  and  Killip  class,  and  a  greater  pro-
ortion of  sinus  rhythm  at  admission  were  seen  among
urrent smokers.  ST-elevation  myocardial  infarction  (STEMI)
as more  common  in  smokers  and  non-ST-elevation  ACS  in





Table  2  Clinical  presentation  of  patients  admitted  with  acute  co
All  (n=2727)  Current  smok
Main  symptoms
Typical  pain,  %  86.2  90.0  
Atypical  pain,  %  7.4  6.4  
Heart  failure,  %  1.9  0.8  
Syncope,  %  1.7  1.1  
Cardiac  arrest,  %  0.8  0.9  
Vital  signs  and  ECG  features
SBP, mmHg  134±35  130±38  
DBP,  mmHg  80±20  80±21  
HR,  bpm  79±25  77±26  
Sinus  rhythm,  %  92.2  97.0  
AF,  %  6.8  2.8  
Paced  rhythm,  %  1.0  0.2  
LBBB,  %  3.7  1.4  
RBBB,  %  4.5  3.3  
Complete  AV  block,  %  2.2  2.6  
Killip  class
I, %  85.8  90.8  
II,  %  9.1  5.7  
III,  %  2.7  1.4  
IV,  %  2.3  2.1  
Type  of  ACS
STEMI, %  61.3  69.8  
NSTEMI,  %  32.4  25.2  
Unstable  angina,  %  6.3  4.9  
ACS: acute coronary syndrome; AF: atrial ﬁbrillation; AV: atrioventri
electrocardiographic; HR: heart rate; LBBB: left bundle branch block
myocardial infarction; NSTEMI: non-ST-segment elevation myocardial iM.  Coutinho  Cruz  et  al.
Table  3  displays  the  laboratory,  echocardiographic  and
ngiographic data  of  the  population.  Median  BNP/NT-pro-
NP, creatinine  and  glucose  values  were  lower  and  median
emoglobin levels  were  higher  in  smokers  compared  to
ever-smokers. Left  ventricular  systolic  dysfunction  as
ssessed by  transthoracic  echocardiography  (left  ventricular
jection fraction  <50%)  was  observed  less  often  in  smokers,
ho also  had  a  lower  proportion  of  multivessel,  left  main
nd left  anterior  descending  artery  disease.
In-hospital  complications  were  least  frequent  in  smok-
rs. They  were  more  often  treated  by  PCI,  but  there  was  no
ifference in  CABG.  Prescription  of  aspirin,  P2Y12 inhibitors,
tatin and  diuretics  during  hospital  stay  and  after  discharge
as signiﬁcantly  lower  in  never-smokers.  Beta-blockers
ere more  widely  used  in  the  smokers  group  at  discharge.
here was  no  difference  in  the  use  of  angiotensin-converting
nzyme inhibitors  (ACEIs)/angiotensin  receptor  blockers
ARBs), either  in-hospital  or  at  discharge.  Smokers  were
ore frequently  discharged  on  a  combination  of  aspirin,
2Y12 inhibitors  and  statins,  and  also  on  a  combination
f these  three  drugs  plus  ACEIs/ARBs  and  beta-blockers
Table 4).
In-hospital mortality  in  smokers  was  a  third  of  that  for
ever-smokers (2.3%  vs.  6.9%,  p<0.001).  The  composite
utcome of  all-cause  mortality,  rehospitalization  for  cardio-
ascular causes,  angiography,  PCI  and  CABG  at  one  year  was
igniﬁcantly lower  in  smokers  (16.2%  vs.  21.4%,  p=0.014),
ronary  syndrome  according  to  smoking  status.






















cular; bpm: beats per min; DBP: diastolic blood pressure; ECG:
; RBBB: right bundle branch block; STEMI: ST-segment elevation
nfarction; SBP: systolic blood pressure.
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Table  3  Laboratory,  echocardiographic  and  angiographic  data  of  patients  admitted  with  acute  coronary  syndrome  according
to  smoking  status.
All  (n=2727)  Current  smokers  (n=1138)  Never-smokers  (n=1589)  p-value
Laboratory  features
BNP/NT-pro-BNP  (admission),  times  ULN  1.98±4.33  2.19±4.85  4.10±6.52  <0.001
BNP/NT-pro-BNP  (maximum),  times  ULN  5.00±16.00  6.00±10.00  8.00±19.00  <0.001
Creatinine  (admission),  mg/dl  1.06±0.31  1.03±0.23  1.10±0.30  <0.001
Glucose  (admission),  mg/dl  145±67  132±60  141±78  <0.001
Glucose  (maximum),  mg/dl  163±84  147±64  165±93  <0.001
Hemoglobin  (admission),  10  g/dl  14.0±3.0  14.0±2.0  13.0±2.0  <0.001
Hemoglobin  (minimum),  10  g/dl 12.0±3.0 13.0±3.0 12.0±3.0 <0.001
LVEF
>50%, % 65.6 70.4 62.7 <0.001
35%-50%,  %  26.8  24.3  28.3  0.022
<35%,  %  7.6  5.3  9.0  <0.001
Angiographic  features
1-vessel disease,  %  48.1  55.0  43.0  <0.001
2-vessel  disease,  %  28.7  28.0  29.2  0.590
3-vessel  disease,  %  15.1  11.7  17.6  0.001
Left  main  disease,  %  3.1  2.2  3.7  0.019
LAD  disease,  %  51.0  47.3  53.7  0.011
LCx  disease,  %  22.7  22.1  23.1  0.633


























mBNP: brain natriuretic peptide; LAD: left anterior descending arter
NT-pro-BNP: N-terminal pro-brain natriuretic peptide; RCA: right 
driven  by  lower  all-cause  mortality  (3.6%  vs.  6.1%,  p=0.008).
There was  an  increased  proportion  of  PCI  in  smokers  at  one
year (3.9%  vs.  2.9%,  p=0.029)  (Table  4).
When  only  STEMI  was  analyzed,  the  distribution  among
current and  never-smokers  of  all  studied  variables  was  sim-
ilar to  that  previously  described  for  the  whole  spectrum  of
ACS. There  was  a  tendency  for  decreased  time  from  symp-
tom onset  to  ﬁrst  medical  contact  (90±79  min  vs.  106±89
min, p=0.059)  and  a  signiﬁcantly  decreased  time  from  ﬁrst
medical contact  to  reperfusion  (123±113  min  vs.  142±131
min, p=0.002)  in  smokers.  Differences  in  the  studied  varia-
bles were  less  pronounced  for  non-ST-segment  elevation
myocardial infarction  (NSTEMI)  and  unstable  angina.  In-
hospital mortality  and  the  composite  endpoint  at  one  year
were signiﬁcantly  lower  in  smokers  with  STEMI  (2.6  vs.  10.1,
p<0.001 and  16.2  vs.  21.4,  p=0.038,  respectively),  but  there
were no  differences  in  patients  with  NSTEMI  or  unstable
angina.
Smoking was  a  predictor  of  in-hospital  mortality  across
the full  spectrum  of  ACS,  with  an  unadjusted  odds  ratio
(OR) of  0.279  (95%  conﬁdence  interval  [CI]  0.181-0.428,
p<0.001). However,  after  adjusting  for  age,  this  associa-
tion was  weaker  (OR  0.591,  95%  CI  0.362-0.965,  p=0.036)
and when  the  multivariate  model  was  fully  adjusted  for  all
variables with  known  prognostic  signiﬁcance  (age,  gender,
heart rate,  systolic  blood  pressure,  Killip  class,  creatinine
at admission  and  type  of  ACS),  smoking  was  not  an  inde-
pendent predictor  of  in-hospital  mortality  (OR  1.129,  95%
CI 0.345-3.696  p=0.842).  A  similar  interaction  was  seen
for STEMI,  while  for  NSTEMI,  smoking  was  not  a  signiﬁcant
predictor of  in-hospital  mortality  in  the  univariate  analysis.
There were  no  in-hospital  deaths  in  patients  with  unstable
‘
t
hx: left circumﬂex artery; LVEF: left ventricular ejection fraction;
ary artery; times ULN: times above the upper limit of normal.
ngina.  This  distribution  was  reproduced  for  the  composite
utcome at  one  year,  and  additionally,  smoking  was  also  not
 predictor  in  univariate  analysis  in  patients  with  unstable
ngina (Table  5).
iscussion
ur  analysis  portrays  a  signiﬁcant  number  of  patients  with
CS admitted  to  a  tertiary  cardiology  center.  We  excluded
atients who  were  treated  by  thrombolysis  in  view  of  the
eed to  adjust  for  the  previously  described  enhanced  effect
f this  therapy  in  smokers.14--16
The  overall  prevalence  of  smoking  in  this  study  is  similar
o those  previously  published.3,26,30 The  decision  to  exclude
ormer smokers  was  based  on  the  fact  that  they  are  known  to
ave a  proﬁle  and  prognosis  intermediate  between  current
mokers and  never-smokers,  and  also  include  a  signiﬁcant
umber of  patients  with  previously  known  coronary  artery
isease, including  myocardial  infarction,12,26,31 which  could
ave biased  the  results.
Smoking is  an  important  determinant  of  coronary  artery
isease, as  shown  by  the  fact  that  the  smokers’  cohort
uffered an  ACS  on  average  15  years  before  never-
mokers, despite  having  fewer  conventional  cardiovascular
isk factors.  The  prevalence  of  dyslipidemia  was  higher  in
urrent smokers,  an  association  that  has  been  described
reviously.32 Current  smokers  were  also  more  frequently
ale, which  emphasizes  an  association  with  another  studiedparadox’ in  ACS.33--35
The  comorbidity  proﬁle  of  smokers  is  less  severe  and
heir presentation  is  more  typical,  an  observation  that  could
ave accounted  for  patients  seeking  help  more  promptly,
852  M.  Coutinho  Cruz  et  al.
Table  4  Complications,  treatment  and  outcome  of  patients  admitted  with  acute  coronary  syndrome  according  to  smoking
status.
All  (n=2727)  Current  smokers  (n=1138)  Never-smokers  (n=1589)  p-value
In-hospital  complicationsa
No  complications,  %  70.3  77.0  66.4  <0.001
Acute  pulmonary  edema,  %  3.5  1.9  4.3  <0.001
Acute  renal  failure,  %  4.5  1.8  6.1  <0.001
Asystole,  %  2.7  1.1  3.6  <0.001
Blood  transfusion,  %  2.3  1.5  2.8  0.023
Cardiogenic  shock,  %  5.1  3.3  6.2  <0.001
Free  wall  rupture,  % 0.4 0.1 0.5 0.047
Mechanical ventilation,  % 5.7 4.0 6.6 0.003
Recurrent  ischemia,  % 0.4 0.1 0.6 0.032
In-hospital treatment
Revascularization,  %  73.8  84.1  67.0  <0.001
PCI  % 71.1  82.4  65.3  <0.001
CABG,  % 1.8  1.7  1.9  0.672
Aspirin,  % 97.5  98.2  97.0  0.037
P2Y12 inhibitor,  % 93.7 96.4  92.1  <0.001
Statin,  % 92.2 94.4 91.0  0.001
ACEI/ARB,  % 87.5 87.2  87.6  0.707
Beta-blocker,  % 60.1 61.9 59.0  0.119
Diuretic,  % 22.2 13.4  27.8  <0.001
Triple  therapy,  %b 87.6 91.9 84.5  <0.001
Quintuple  therapy,  %c 49.8 52.7 47.8 0.011
Discharge  treatment
Aspirin, %  89.4  94.0  86.7  <0.001
P2Y12 inhibitor,  %  82.7  90.0  78.5  <0.001
Statin,  %  86.8  91.9  83.8  <0.001
ACEI/ARB,  %  78.8  80.0  78.1  0.228
Beta-blocker,  %  55.8  59.4  53.7  0.002
Diuretic,  %  22.1  12.7  27.5  <0.001
Triple  therapy,  %b 78.5  86.0  73.1  <0.001
Quintuple  therapy,  %c 42.9  45.6  41.0  0.016
In-hospital  mortality,  %  5.2  2.3  6.9  <0.001
Composite  outcome  at  1  year,  % 19.2 16.2  21.4  0.014
All-cause  mortality,  %  5.3  3.9  6.1  0.008
Rehospitalization,  %  7.9  9.0  7.1  0.194
Angiography,  %  5.0  6.6  3.9  0.019
PCI,  %  3.0  4.1  2.2  0.031
CABG,  % 1.6  1.1  2.0  0.179
a In-hospital complications with non-signiﬁcant differences between the groups: complete atrioventricular heart block, ﬁrst or second
degree atrioventricular heart block, minor or major bleeding, need for hemodialysis, new bundle branch block, new Q-wave develop-
ment, reinfarction, severe mitral regurgitation, tamponade, septal rupture, stroke/transient ischemic attack, ventricular ﬁbrillation,
ventricular tachycardia.
b Combination of aspirin, P2Y12 inhibitor and statin.












aACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin r
artery disease; PCI: percutaneous coronary intervention; STEMI: S
hich  is  in  part  suggested  by  the  tendency  for  lower  time
rom symptom  onset  to  ﬁrst  medical  contact  (reported
nly in  STEMI).  Smoking  has  been  associated  with  delay  in
eeking treatment,36 which  was  not  seen  in  our  analysis;
his could  be  related  to  smokers’  younger  age  and  larger
roportion of  male  subjects.37 Smokers  are  also  more  prone
o present  with  ACS  as  the  ﬁrst  manifestation  of  coronary
n
a
sor blocker; CABG: coronary artery bypass grafting; CAD: coronary
vation myocardial infarction.
rtery  disease,  since  a  history  of  this  entity  is  less  frequent
n this  group.
Smokers have  lower  heart  rate  and  systolic  blood  pressure
t admission,  as  well  as  lower  Killip  class  and  creati-
ine levels,  which  are  known  predictors  of  better  outcome
nd puts  them  at  an  advantage  when  compared  to  never-
mokers.38
Smoker’s  paradox  in  acute  coronary  syndrome  853
Table  5  Inﬂuence  of  smoking  on  in-hospital  mortality  and  on  the  composite  outcome  of  all-cause  mortality,  rehospitalization
for  cardiovascular  causes,  angiography,  PCI  and  CABG  at  one  year  according  to  type  of  acute  coronary  syndrome.
Crude  OR  (95%  CI)  Age-adjusted  OR  (95%  CI)  Fully-adjusted  ORa (95%  CI)
In-hospital  mortality
All ACS  0.279  (0.181-0.428),  p<0.001  0.591  (0.362-0.965),  p=0.036  0.903  (0.472-1.727),  p=0.757
STEMI 0.236  (0.144-0.387),  p<0.001  0.521  (0.295-0.921),  p=0.025  0.835  (0.394-1.770),  p=0.638
NSTEMI 0.427  (0.174-1.048),  p=0.063  1.094  (0.391-3.059),  p=0.864  1.024  (0.274-3.827),  p=0.972
UA -  -  -
Composite outcome  of  all-cause  mortality,  rehospitalization  for  cardiovascular  causes,  angiography,  PCI  and  CABG  at  1  year
All ACS  0.675  (0.509-0.894),  p<0.001  0.873  (0.624-1.220),  p=0.426  0.925  (0.623-1.373),  p=0.699
STEMI 0.772  (0.540-1.104),  p=0.156  0.781  (0.513-1.190),  p=0.250  0.822  (0.503-1.344),  p=0.435
NSTEMI 0.548  (0.325-0.923),  p=0.024 1.158  (0.616-2.175),  p=0.648 1.174  (0.564-2.445),  p=0.667
UA 0.972  (0.254-3.726),  p=0.967 1.434  (0.311-6.613),  p=0.644 1.604  (0.191-13.449),  p=0.663
a Variables inserted in the model were age, gender, heart rate, systolic blood pressure, Killip class, creatinine at admission and type



























1. Gaziano TA, Prabhajaran D, Gaziano JM. Global burden of car-
diovascular disease. Chapter 1. In: Mann, Zipes, Libby, Bonow,
editors. Braunwald’s Heart Disease. A textbook of cardiovascu-
lar medicine. Philadelphia: Saunders Elsevier; 2015. p. 1--20.ACS:  acute coronary syndrome; NSTEMI: non-ST-elevation myocard
angina.
Current  smokers  have  a  greater  propensity  for
STEMI.3,26,28,30 Their  coronary  anatomy  is  less  complex,
with less  three-vessel  disease  and  fewer  left  main  and  left
anterior descending  lesions,  features  that  are  typically
associated with  a  worse  prognosis.39
The  rate  of  adherence  to  evidence-based  treatment  was
greater in  smokers,  both  during  the  index  hospitalization
(revascularization  and  medical  treatment)12,26,29--31 and  at
discharge (medical  treatment).31 Moreover,  smokers  were
treated more  promptly  than  never-smokers,  as  shown  by
a signiﬁcantly  shorter  time  from  ﬁrst  medical  contact  to
reperfusion (reported  only  in  STEMI).11
In-hospital  mortality  in  smokers  was  a  third  of  that  for
never-smokers. Although  the  composite  outcome  of  all-
cause mortality,  rehospitalization  for  cardiovascular  causes,
angiography, PCI  and  CABG  at  one  year  was  lower  in  smok-
ers, mainly  due  to  lower  all-cause  mortality,  there  was  a
signiﬁcantly increased  rate  of  repeat  PCI  in  this  group.  This
association has  been  described  in  previous  reports.40--42
Smoking  wa-s  associated  with  in-hospital  mortality  and
adverse outcome  at  one  year,  particularly  in  STEMI,  but
this association  was  weaker  after  adjustment  for  age  and
disappeared when  other  variables  with  known  prognostic
impact38 were  inserted  into  the  model.  Other  reports  have
shown that  age  may  be  the  sole  factor  responsible  for  the
smoker’s paradox.25,26 This  was  not  the  case  in  our  popula-
tion, in  which  other  variables  related  to  clinical  presentation
were also  important.  Smoking  had  no  inﬂuence  on  outcome
in patients  with  NSTEMI  and  unstable  angina,  which  is  in
agreement with  the  initial  reports  of  the  smoker’s  paradox,
which referred  to  STEMI  only.9,26,43
This  study  has  some  limitations.  First,  it  was  retrospec-
tive in  nature  and  thus  susceptible  to  inherent  limitations.
Second, it  was  not  possible  to  determine  the  number  of
pack-years in  all  smokers.  Third,  out-of-hospital  deaths  were
not  recorded.  Fourth,  there  were  no  data  regarding  adher-
ence to  medical  treatment  after  discharge.farction; STEMI: ST-elevation myocardial infarction; UA: unstable
onclusion
urrent  smokers  with  ACS  were  signiﬁcantly  younger
nd more  frequently  male,  had  fewer  risk  factors  and
omorbidities, more  benign  clinical  presentation  and
ewer complications,  and  received  more  aggressive  treat-
ent. These  differences  completely  explained  the  lower
n-hospital and  one-year  mortality  initially  observed  in  cur-
ent smokers.  Thus,  in  our  population,  we  did  not  ﬁnd  a  real
moker’s paradox.  Besides,  the  apparent  beneﬁt  was  only
een in  the  subset  of  patients  with  STEMI,  while  differences
n overall  characteristics  were  less  marked  in  other  types  of
CS and  no  beneﬁt  in  mortality  was  seen.  Importantly,  ACS
n smokers  occurs  around  15  years  before  never-smokers,
hich makes  smoking  a major  cardiovascular  risk  factor  and
 target  for  primary  and  secondary  prevention  of  ischemic
eart disease.
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